Novartis has signed deals with Intellia Therapeutics and Caribou Biosciences that Reuters says gives the drugmaker access to using the CRISPR genome-editing technology to develop new therapeutics and as a research tool.
Registering provides access to this and other free content.
Already have an account?Login Now.
The New York Times reports that as China invests in science, it also is dealing with research fraud.
In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.
The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.
Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.